Multiple Sclerosis

Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.

In an observational cohort study, factors such as education, income, and marital status correlated with MS severity outcomes.

Researchers conducted a cohort study that suggests oral N-acetylglucosamine treatment can hinder neurodegeneration and inflammation associated with multiple sclerosis (MS).

Findings showed that autonomic symptom burden was slightly more severe in patients with multiple sclerosis (MS) compared with those with NMOSD, although the difference was not statistically significant.

In a retrospective, real-world cohort study, the factors complicating the diagnosis of primary progressive forms of multiple sclerosis (PPMS) were explored.

Researchers add to previous studies by refuting association between vaccines and MS flare-ups.

With their final thoughts, the panelists emphasize patient-centered care is at the forefront of critical MS treatment considerations for providers.

A comprehensive look into MS treatment objectives is provided.

The rise of telehealth during COVID-19, its limitations, and its uncertain future.

Video games that involve physical exertion was found to be more effective at improving balance in patients with multiple sclerosis (MS) compared with more conventional rehabilitation methods, investigators concluded.

A review of published literature revealed which diet methods and forms of physical activity are most effective at improving patient-reported outcomes in patients with multiple sclerosis (MS).

The top 5 most-read multiple sclerosis articles of 2021 focused on artificial intelligence, sunlight exposure, and COVID-19 risk factors, responses, and guidance for people with multiple sclerosis.

After administration of a COVID-19 vaccine, patients with multiple sclerosis (MS) taking ocrelizumab (Ocrevus) or fingolimod (Gilenya) may find themselves less protected against COVID-19 than the general population.

Obesity was found to have a significant association with retinal structure abnormalities related to multiple sclerosis (MS); however, the impact may be greater for African Americans than Caucasian Americans.

Coping strategies can play a role in influencing the health-related quality of life and physical disability of people with multiple sclerosis (MS), researchers concluded.

Researchers recommend vaccination against COVID-19 for patients with multiple sclerosis (MS) after confirming that several types of vaccines are safe and produced no significant adverse events.

Although obesity, diabetes, and certain comorbidities were all detected as risk factors for severe COVID-19 among people with multiple sclerosis (MS), other long-suspected risk factors, such as smoking and use of most disease-modifying therapies (DMTs), were not.

Changes to diet, wellness, and physical activity could have a profound effect on patients’ ability to manage their multiple sclerosis (MS) and significantly improve their quality of life at the same time, researchers concluded.

A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past research.

On this episode of Managed Care Cast, hear from a multiple sclerosis (MS) specialist about how millennial patients are different (or not) in how they approach their disease.

Body mass index (BMI) was not identified as a factor influencing cognitive function or brain mass in patients with relapsing-remitting multiple sclerosis (RRMS), investigators of a recent analysis concluded.

In a study assessing the impacts of 5 growth factors on MS, fibroblast growth factor 23 was identified to increase the risk of patients experiencing the onset and progression of multiple sclerosis (MS).

The European Commission gave its stamp of approval for Vumerity (diroximel fumarate), developed by Biogen, as an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS).

Anti-CD20 disease-modifying therapies, including rituximab and ocrelizumab, were found to increase the risk of hospitalization and intensive care unit admission in patients with multiple sclerosis (MS) who develop COVID-19, investigators concluded in this new study.